Fighting Forgetfulness with Nanotechnology
October 17, 2018 | Max Planck Institute for Polymer ResearchEstimated reading time: 2 minutes
About 29 million people around the world are affected by the disease "Alzheimer." In an international collaboration, scientists of the Max Planck Institute for Polymer Research (MPI-P) in Mainz together with teams from Italy, Great Britain, Belgium and the USA are now working together on an approach for a therapy. On the one hand, the goal is to understand the processes occurring in the brain that lead to the disease; on the other hand the development of a method for targeted drug delivery.
In the human brain, nerve cells—so-called neurons—care for the transmission of electrical signals. They form the functional component responsible for sensations, stimuli and memories. In the presence of dementia, there is an adsorption of proteins outside the neurons, which then leads to the death of the neuronal cells. How to prevent the death of neurons is still the subject of scientific research today.
In a recent transnational research project funded by the EU Joint Program on Neurodegenerative Disease Research (JPND), which is funded in Germany by the German Federal Ministry of Education and Research (BMBF), researchers are now trying to address this question.
While project partners in Italy, Great Britain, Belgium and the USA investigate the exact processes in the brain, the MPI-P explores methods to transport drugs. The overcoming of a natural barrier in the body—the so-called blood-brain barrier—represents the main challenge. Drugs to be used in the brain must be able to pass this barrier first before acting in the brain.
For this purpose, the Mainz scientists are working on nanocapsules that are supposed to overcome the barrier. On the one hand, it has to be taken care on a long circulation time of the nanocapsules in the blood in order to increase the probability of interaction with the target cells in the affected brain areas. For this, it is important to design the nanocapsules so that they are not directly excreted by kidney or liver. On the other hand, special "address labels"—consisting of proteins—must be placed on the capsule surface in order to be recognized and absorbed by the target cells, much like a key with a lock. "We are still filling our nanoscale capsules with dye," says Dr. Svenja Morsbach, group leader in the department of Prof. Katharina Landfester at the MPI-P. "If the transport through the blood-brain barrier with the nanocarriers works, we hope we can simply exchange the dye for a suitable drug."
The partners involved in the project in Italy, the United Kingdom, Belgium and the USA are examining the exact processes in the brain in parallel with the development of the transport system in Mainz. Here, so-called "exosomes" and "neurotrophic factors" are of major interest. Exosomes are small "miniature cells" that can be released by real cells to communicate with each other. These have a dimension of only about 100 nanometers—that is 100 billionths of a meter in size. At the same time, "neurotrophic factors" are biochemical messengers responsible for the growth and survival of nerve cells. The interaction of exosomes and neuron-stimulating factors is seen as the main focus for the understanding of dementia by researchers.
The project is designed for a period of three years and is funded with over one million euro, of which a share of more than 400,000 euros is attributed to the subproject of the Mainz scientists. The researchers hope that understanding the disease itself and developing a functioning transport system will be an important step in the treatment of dementia.
Suggested Items
U.S. Department of Commerce Announces $1.4 Billion in Final Awards to Support the Next Generation of U.S. Semiconductor Advanced Packaging
01/17/2025 | U.S. Department of CommerceThe U.S. Department of Commerce has announced that CHIPS National Advanced Packaging Manufacturing Program (NAPMP) has finalized $1.4 billion in award funding to bolster U.S. leadership in advanced packaging and enable new technologies to be validated and transitioned at scale to U.S. manufacturing.
RIKEN Adopts Siemens' Emulation And High-Level Synthesis Platforms for Next-Generation AI Device Research
01/16/2025 | SiemensSiemens Digital Industries Software announced today that RIKEN, a national research and development agency in Japan, is enhancing its research on next-generation AI devices with Siemens' comprehensive Veloce™
SIA Releases Policy Recommendations for Trump-Vance Administration and 119th Congress
01/16/2025 | SIAThe Semiconductor Industry Association (SIA) released a policy agenda setting forth the U.S. semiconductor industry’s policy priorities and suggested areas for collaboration with the Trump-Vance administration and the 119th Congress.
Argonne to Lead Two Microelectronics Research Projects Under U.S. Department of Energy Initiative
01/13/2025 | BUSINESS WIREThe U.S. Department of Energy’s (DOE) Argonne National Laboratory is managing two microelectronics studies that will support multidisciplinary codesign of hardware and software and enable processing of vast quantities of data at unprecedented speeds.
NASA’s Kennedy Marks New Chapter for Florida Space Industry
01/09/2025 | NASAThe future of research and technology at NASA’s Kennedy Space Center in Florida is expanding Wednesday, as Kennedy’s center director and charter members in the Florida University Space Research Consortium signed a memorandum of understanding in research and development to assist with missions and contribute to NASA’s Moon to Mars exploration approach.